Drugs / CD19.20.22 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07168486 | Oct 2024 → Jul 2027 expected | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +2 | University of Maryland, Baltimore | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19.20.22 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168486 ↗ |
| Modality | Cell therapy | “CAR19.20.22 is a type of immunotherapy known as a chimeric antigen receptor T-cells (CAR T-cells).” NCT07168486 ↗ |
| Route | Intravenous | “IV infusion” NCT07168486 ↗ |